X
Log In
Username or E-mail:
Password:
EULA
Log In
Forgot Password
Sign Up
Sign Up
Username:
E-mail:
Password:
EULA
Sign Up
Forgot Password
Already a Member
Username or E-mail
Send Forgot Mail
Back to Login
EULA
X
Share This!
Sign Up
Log In
Logout
X
English Türkçe

IMAB

Closed

I-mab

2.34
-0.08 (-3.31%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 2.42
Day's Range: 2.2402 - 2.5
Send
When Written:
 
3.64
I-Mab is a biopharmaceutical company that focuses on the discovery and development of innovative biologics for the treatment of cancer and autoimmune diseases. The company was founded in 2016 and is headquartered in Shanghai, China, with additional offices in the United States and Europe.

I-Mab's pipeline includes several novel drug candidates, including TJ202, a monoclonal antibody for the treatment of solid tumors, and TJ101, a monoclonal antibody for the treatment of rheumatoid arthritis. The company has also partnered with other biopharmaceutical companies to develop and commercialize its drug candidates in different regions of the world.

I-Mab has received significant funding from various sources, including venture capital firms, strategic investors, and public offerings. The company is committed to advancing its pipeline and bringing innovative therapies to patients in need.

Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
Contact with us

Mail:
Message:
Cancel
Send
IP Adresiniz:216.73.216.58
X